Comparing Epclusa vs Ribavirin
Epclusa (sofosbuvir / velpatasvir) | Ribavirin |
|
---|
Epclusa (sofosbuvir / velpatasvir) | Ribavirin |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Epclusa is a combination tablet containing velpatasvir and sofosbuvir. It may be used to treat all six genotypes of the hepatitis C virus in adults and children over the age of three. It is usually... View more |
Prescription only
Prescribed for Hepatitis C, RSV. Ribavirin may also be used for purposes not listed in this medication guide. |
Related suggestions Hepatitis C
Popular comparisons
|
|||||||||||||||
More about Epclusa (sofosbuvir / velpatasvir) | More about Ribavirin | ||||||||||||||||
Ratings & Reviews | |||||||||||||||||
Epclusa has an average rating of 7.6 out of 10 from a total of 399 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 12% reported a negative effect. |
Ribavirin has an average rating of 4.8 out of 10 from a total of 10 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 50% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Epclusa side effects |
View all Ribavirin side effects |
||||||||||||||||
Drug Class | |||||||||||||||||
Generic Availability | |||||||||||||||||
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Epclusa prices |
View all Ribavirin prices |
||||||||||||||||
Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
Brand Names | |||||||||||||||||
N/A |
Rebetol, RibaTab, Virazole | ||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
27 hours |
960 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | |||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | |||||||||||||||||
A total of 200 drugs are known to interact with Epclusa:
|
A total of 18 drugs are known to interact with Ribavirin:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
Disease Interactions | |||||||||||||||||
First Approval Date | |||||||||||||||||
June 28, 2016 |
June 03, 1998 |
||||||||||||||||
WADA Class View classifications | |||||||||||||||||
N/A |
N/A |
||||||||||||||||
More Information | |||||||||||||||||
Patient Resources | |||||||||||||||||
Professional Resources | |||||||||||||||||
Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Harvoni
Harvoni is used to treat hepatitis C virus (HCV) infections in adults and children aged 3 years and ...
Mavyret
Mavyret (glecaprevir/pibrentasvir) is an oral combination medicine containing fixed doses of two ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Sovaldi
Sovaldi (sofosbuvir) is used to treat chronic hepatitis C virus (HCV) infection. Includes Sovaldi ...
Pegasys
Pegasys is used to treat chronic hepatitis B or C. Learn about side effects, interactions and ...
Vosevi
Vosevi (sofosbuvir,velpatasvir and voxilaprevir) is used to treat chronic hepatitis C. Includes ...
Zepatier
Zepatier (elbasvir and grazoprevir) is used to treat chronic hepatitis C. Includes Zepatier side ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.